This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Inflectra® (infliximab) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Rheumatoid Arthritis safety guidance

Important Safety Information

​​​​​​​

The Inflectra Summary of Product Characteristics (SPC) should be read and understood in full before prescribing this medicine.1

Inflectra MUST NOT be given in:

  1. Cases of tuberculosis, or other severe infections such as sepsis, abscesses and opportunistic infections
  2. Patients with a history of hypersensitivity to infliximab (or any of its excipients) or other murine proteins
  3. Patients with moderate or severe heart failure (NYHA class III/IV)

Also consider the safety and screening recommendations below for any patient diagnosed with Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and severe plaque psoriasis for whom you are considering initiating Inflectra:1

Actively screen and monitor patients for infections

Screenings for latent/active tuberculosis and hepatitis B

Vaccinate

Bring paediatric patients up to date with all vaccinations prior to intiating treatment if possible

Monitor

The general condition of patients (e.g. symptoms of bacterial or viral infections, fever, ulcers, or purulent discharge from fistulas)

Discuss potential health issues with patients

  • Heart problems
  • Lymphoma or other cancer
  • Lung disease or heavy smoking
  • Problems that affect the nervous system, such as multiple sclerosis, Guillain-Barre syndrome, or optic neuritis
  • Abnormal skin openings
  • Imminent operations
  • Dental issues, including planned operations or procedures

Consider the long half-life of infliximab when planning certain vaccinations or surgical procedures

Closely monitor patients who require surgery for infections

Avoid concurrent administration of Inflectra with live vaccines or therapeutic infectious agents such as live attenuated bacteria

Also avoid administration of live vaccines in infants ‚<6 months of age who have been exposed to infliximab in utero

Explore more

Evidence – Rheumatoid arthritis

Learn about the clinical evidence supporting the use of Inflectra in patients with rheumatoid arthritis

Learn more

Rheumatoid arthritis dosing

Learn about the dosing and administration of Inflectra in patients with rheumatoid arthritis

Find out more


*CT-P13 is marketed under different brand names including Inflectra and REMSIMA®.
CD=Crohn's disease; UC=Ulcerative colitis; CRP=C-reactive protein.
References
  1. Inflectra Summary of Product Characteristics.
PP-IFA-GBR-0434. March 2021

Quick Links

Read about the safety profile and contraindications with Inflectra in patients with Crohn's disease. 

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No